Related Experiment Video
Updated: Oct 9, 2025

RNA Interference-based Investigation of the Function of Heat Shock Protein 27 during Corneal Epithelial Wound Healing
Published on: September 27, 2016
HDAC9 in the Injury of Vascular Endothelial Cell Mediated by P38 MAPK Pathway
Xi Kuang1,2, Shuang Chen1,2, Jitong Lao1,2
1Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
Insights
Histone deacetylase 9 (HDAC9) promotes inflammatory injury in vascular endothelial cells, contributing to atherosclerosis and ischemic stroke. Inhibiting HDAC9 with sodium valproate may offer a potential treatment strategy.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Neuroscience
Background:
- Atherosclerosis (AS) and ischemic stroke significantly impact human health.
- Genome-wide association studies link histone deacetylase 9 (HDAC9) expression in atheromatous plaques to ischemic stroke.
- The precise molecular mechanisms remain unclear.
Purpose of the Study:
- To investigate the role of HDAC9 in oxidized low-density lipoprotein (ox-LDL)-induced inflammatory injury in vascular endothelial cells.
- To explore the involvement of the P38 mitogen-activated protein kinase (P38 MAPK) pathway in HDAC9-mediated AS.
- To evaluate the therapeutic potential of HDAC9 inhibition for ischemic stroke.
Main Methods:
- Knockdown of HDAC9 in vascular endothelial cells using short hairpin RNA (shRNA).
- Assessment of P38 MAPK phosphorylation levels.
- Treatment with sodium valproate (SVA), a HDAC9 inhibitor, and SB203580, a P38 MAPK inhibitor.
Main Results:
- HDAC9 knockdown reduced ox-LDL-induced inflammatory injury in vascular endothelial cells.
- HDAC9 regulates the phosphorylation of P38 MAPK, a key inflammatory pathway.
- Sodium valproate (SVA) and SB203580 antagonized inflammatory damage in vascular endothelial cells.
Conclusions:
- HDAC9 mediates ox-LDL-induced inflammatory injury in vascular endothelial cells by modulating P38 MAPK phosphorylation, contributing to AS.
- HDAC9 is a potential therapeutic target for preventing and treating atherosclerotic plaques.
- Sodium valproate (SVA) shows promise as a potential drug for ischemic stroke prevention and treatment.
Abstract:
Ischemic stroke caused by atherosclerosis (AS) poses a serious threat to human life expectancy and quality. With the development of genome-wide association studies, the association of histone deacetylase 9 (HDAC9) expression of atheromatous plaques with ischemic stroke in large arteries has been revealed, but the molecular mechanisms behind this phenomenon have not been elucidated. In this study, we explored the effect of HDAC9 on the P38 mitogen activated protein kinase (P38 MAPK), a classic cellular inflammation-related pathway, by knocking down HDAC9 in vascular endothelial cells with short hairpin RNA (shRNA) and found that HDAC9 may mediate oxidized low density lipoprotein (ox-LDL)-induced inflammatory injury in vascular endothelial cells by regulating the phosphorylation level of P38 MAPK to lead to AS. It can be seen that HDAC9 may be a target to control the formation of atherosclerotic plaques. In follow-up experiments, it was verified that sodium valproate (SVA), as a HDAC9 inhibitor, can indeed antagonize the inflammatory damage of vascular endothelial cells, as well as SB203580, which is a P38 MAPK inhibitor. It proves that SVA may be a potential drug for the prevention and treatment of ischemic stroke.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
MAPK Signaling Cascades
DNA Damage can Stall the Cell Cycle
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Hedgehog Signaling Pathway

